Pfizer Corporation

Pharmacia & Upjohn Company

Pharmacia & Upjohn

Jeffrey W Corbett

Patrick Robert Verhoest

Kristine E Frank

Jian-Min Fu

Michael D Ennis

Robert Louis Hoffman

Eric Jon Jacobsen

David W Piotrowski

Vincent E Groppi, Jr

Bruce Nelsen Rogers

Jason K Myers

Alice L Bodnar

Donn G Wishka

David Andrew Griffith

Dennis Paul Phillion

Daniel Patrick Walker

Brad A Acker

Kevin Daniel Freeman-Cook

Richard Louis Elliott

Mark R Rauckhorst

The invention provides compounds of Formula (1) or a pharmaceutically acceptable salt of said compound, wherein R, R, and Rare as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of acetyl-CoA carboxylase enzyme(s) in an animal. 

Pyrazolospiroketone acetyl-CoA carboxylase inhibitors

The present invention relates to compounds of Formula I, or a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a prodrug thereof. The compounds of the inventions are CRFreceptor antagonists. Compounds of the invention are useful for treating, in a warm-blooded animal, particularly a mammal, and more particularly a human, various disorders that are associated with CRF or CRFreceptors, or disorders the treatment of which can be effected or facilitated by antagonizing CRFreceptors.

[object Object]

This invention relates to compounds of Formula I, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, a prodrug thereof, or a pharmaceutically acceptable salt of a prodrug thereof. The compounds interact with CRFreceptors, including human CRFreceptors. This invention also relates to methods of using the compounds of the invention to treat a disorder or condition, the treatment of which can be effected or facilitated by antagonizing a CRF receptor, such as CNS disorders or diseases, particularly anxiety-related disorders such as anxiety, and mood disorders such as major depression.

Substituted pyrimidine derivatives

Substituted aryl pyrazine derivatives of the formula I as defined herein,and their use in treating anxiety disorders, depression and stress related disorders are disclosed.

Substituted aryl 1, 4-pyrazine derivatives

This invention relates to substituted pyrimidinone and pyrimidithione derivatives that bind with high affifnity to CRF1 receptors, including human CRF1 receptors. This invention also relates to methods of using the compounds of the invention to treat a disorder or condition, the treatment of which can be effected or facilitated by antagonizing a CRF receptor, such as CNS disorders or diseases, particularly anxiety disorders, and depression and stress related disorders.

Substituted pyrimidinones and pyrimidinthiones

Substituted aryl 1,4-pyrazine derivatives of formula I as defined hereinand their use in treating anxiety disorders, depression and stress related disorders are disclosed.

Substituted aryl 1,4-pyrazine derivatives

The present invention provides substituted pyrazine derivatives of Formula I,that are CRFreceptor antagonists, including human CRFreceptors. This invention also relates to use of compounds of the invention for treating a disorder or condition, the treatment of which can be effected or facilitated by antagonizing a CRF receptor, such as CNS disorders, particularly anxiety-related disorders and mood disorders.

Substituted pyrazine derivatives

The invention provides compounds of Formula I:wherein Azabicyclo is These compounds may be in the form of pharmaceutical salts or compositions, may be in pure enantiomeric form or racemic mixtures, and are useful in pharmaceuticals in which &#x3b1;7 is known to be involved.

N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease

Quinuclidine-substituted heteroaryl moieties for treatment of disease

Substituted-heteroaryl-7-aza&lsqb;2.2.1&rsqb;bicycloheptanes for the treatment of disease

Growing community of inventors

Portage, MI, United States of America

Jeffrey W Corbett